Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

Krönke, Jan, Udeshi, Namrata D., Narla, Anupama, Grauman, Peter, Hurst, Slater N., McConkey, Marie, Svinkina, Tanya, Heckl, Dirk, Comer, Eamon, Li, Xiaoyu, Ciarlo, Christie, Hartman, Emily, Munshi, Nikhil, Schenone, Monica, Schreiber, Stuart L., Carr, Steven A., Ebert, Benjamin L.·2014·Science

DOI 10.1126/science.1244851

Cited by (1,006)

Items 101–200 of 1,006

Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
Bjorklund, C C, Lu, L, Kang, J, Hagner, P R, Havens, C G, Amatangelo, M, Wang, M, Ren, Y, Couto, S, Breider, M et al. · 2015 · Blood Cancer Journal
Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15
Faust, Tyler B., Yoon, Hojong, Nowak, Radosław P., Donovan, Katherine A., Li, Zhengnian, Cai, Quan, Eleuteri, Nicholas A., Zhang, Tinghu, Gray, Nathanael S., Fischer, Eric S. · 2020 · Nature Chemical Biology
Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction
Simonetta, Kyle R., Taygerly, Joshua, Boyle, Kathleen, Basham, Stephen E., Padovani, Chris, Lou, Yan, Cummins, Thomas J., Yung, Stephanie L., von Soly, Szerenke Kiss, Kayser, Frank et al. · 2019 · Nature Communications
The novel mechanism of lenalidomide activity
Fink, Emma C., Ebert, Benjamin L. · 2015 · Blood
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
Niels Weinhold, Cody Ashby, Leo Rasche, Shweta S. Chavan, Caleb Stein, Owen Stephens, Ruslana G. Tytarenko, Michael Bauer, Tobias Meißner, Shayu Deshpande et al. · 2016 · Blood
Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation
Lv, Lu, Chen, Peihao, Cao, Longzhi, Li, Yamei, Zeng, Zhi, Cui, Yue, Wu, Qingcui, Li, Jiaojiao, Wang, Jian-Hua, Dong, Meng-Qiu et al. · 2020 · eLife
Immunotherapy of multiple myeloma
Simone A. Minnie, Geoffrey R. Hill · 2020 · Journal of Clinical Investigation
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
Zhu, Yuan Xiao, Braggio, Esteban, Shi, Chang-Xin, Kortuem, K. Martin, Bruins, Laura A., Schmidt, Jessica E., Chang, Xiu-Bao, Langlais, Paul, Luo, Moulun, Jedlowski, Patrick et al. · 2014 · Blood
Cullin–RING ubiquitin E3 ligase regulation by the COP9 signalosome
Cavadini, Simone, Fischer, Eric S., Bunker, Richard D., Potenza, Alessandro, Lingaraju, Gondichatnahalli M., Goldie, Kenneth N., Mohamed, Weaam I., Faty, Mahamadou, Petzold, Georg, Beckwith, Rohan E. J. et al. · 2016 · Nature
The Ubiquitin–Proteasome System in Immune Cells
Gonca Çetin, Sandro Klafack, Maja Studencka‐Turski, Elke Krüger, Frédéric Ebstein · 2021 · Biomolecules
Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management
S. Vincent Rajkumar · 2018 · American Journal of Hematology
Targeted Protein Degradation by Small Molecules
Bondeson, Daniel P., Crews, Craig M. · 2017 · Annual Review of Pharmacology and Toxicology
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
Andrew Jenho Yee, William Bensinger, Jeffrey G. Supko, Peter Michael Voorhees, Jesús G. Berdeja, Paul Gerard Guy Richardson, Edward N. Libby, Ellen E Wallace, Nicole Birrer, Jill N. Burke et al. · 2016 · The Lancet Oncology
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models
Sheryl M. Gough, John J. Flanagan, Jessica L.F. Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan R. Willard, Kim Davenport, Elizabeth Bortolon et al. · 2024 · Clinical Cancer Research
Proximity-Based Modalities for Biology and Medicine
Xingui Liu, Alessio Ciulli · 2023 · ACS Central Science
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL
Hagner, Patrick R., Man, Hon-Wah, Fontanillo, Celia, Wang, Maria, Couto, Suzana, Breider, Mike, Bjorklund, Chad, Havens, Courtney G., Lu, Gang, Rychak, Emily et al. · 2015 · Blood
Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma
James L. Rubenstein, Huimin Geng, Eleanor J. Fraser, Paul E. Formaker, Lingjing Chen, Jigyasa Sharma, Phoebe Killea, Kaylee Choi, Jenny Ventura, John V. Kurhanewicz et al. · 2018 · Blood Advances
Chasing molecular glue degraders: screening approaches
Domostegui, Ana, Nieto-Barrado, Luis, Perez-Lopez, Carles, Mayor-Ruiz, Cristina · 2022 · Chemical Society Reviews
The E3 ligase adapter cereblon targets the C-terminal cyclic imide degron
Ichikawa, Saki, Flaxman, Hope A., Xu, Wenqing, Vallavoju, Nandini, Lloyd, Hannah C., Wang, Binyou, Shen, Dacheng, Pratt, Matthew R., Woo, Christina M. · 2022 · Nature
Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras
Green Ahn, Nicholas McIlvain Riley, Roarke A. Kamber, Simon Wisnovsky, Salvador Moncayo von Hase, Michael Cory Bassik, Steven M. Banik, Carolyn Ruth Bertozzi · 2023 · Science
Molecular glues for protein-protein interactions: Progressing toward a new dream
Markella Konstantinidou, Michelle R. Arkin · 2024 · Cell chemical biology
Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders
Yang, Jiuling, Li, Yangbing, Aguilar, Angelo, Liu, Zhaomin, Yang, Chao-Yie, Wang, Shaomeng · 2019 · Journal of Medicinal Chemistry
Development of the first small molecule histone deacetylase 6 (HDAC6) degraders
Yang, Ka, Song, Yanling, Xie, Haibo, Wu, Hao, Wu, Yi-Ting, Leisten, Eric D., Tang, Weiping · 2018 · Bioorganic & Medicinal Chemistry Letters
Molecular basis of resistance to proteasome inhibitors in hematological malignancies
Denise Niewerth, Gerrit Jansen, Yehuda G. Assaraf, Sonja Zweegman, Gertjan J.L. Kaspers, Jacqueline J Cloos · 2014 · Drug Resistance Updates
Targeted protein degradation as a powerful research tool in basic biology and drug target discovery
Tao Wu, Hojong Yoon, Yuan Xiong, Sarah E. Dixon-Clarke, Radosław P. Nowak, Eric S. Fischer · 2020 · Nature Structural & Molecular Biology
EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis
Jun Wang, Xufen Yu, Weida Gong, Xijuan Liu, Kwang‐Su Park, Anqi Ma, Yi‐Hsuan Tsai, Yudao Shen, Takashi Onikubo, Wen‐Chieh Pi et al. · 2022 · Nature Cell Biology
PROTACs: A novel strategy for cancer therapy
Liu, Jing, Ma, Jia, Liu, Yi, Xia, Jun, Li, Yuyun, Wang, Z. Peter, Wei, Wenyi · 2020 · Seminars in Cancer Biology
PROTACs to address the challenges facing small molecule inhibitors
Pedro Martín-Acosta, Xiangshu Xiao · 2020 · European Journal of Medicinal Chemistry
pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
An, Jian, Ponthier, Charles M., Sack, Ragna, Seebacher, Jan, Stadler, Michael B., Donovan, Katherine A., Fischer, Eric S. · 2017 · Nature Communications
Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity
Eichner, Ruth, Heider, Michael, Fernández-Sáiz, Vanesa, van Bebber, Frauke, Garz, Anne-Kathrin, Lemeer, Simone, Rudelius, Martina, Targosz, Bianca-Sabrina, Jacobs, Laura, Knorn, Anna-Maria et al. · 2016 · Nature Medicine
Cancer Therapy–Associated Thrombosis
Steven Philip Grover, Yohei Hisada, Raj S. Kasthuri, Brandi Reeves, Nigel Mackman · 2021 · Arteriosclerosis Thrombosis and Vascular Biology
Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820
Du, Xinlin, Volkov, Oleg A., Czerwinski, Robert M., Tan, HuiLing, Huerta, Carlos, Morton, Emily R., Rizzi, Jim P., Wehn, Paul M., Xu, Rui, Nijhawan, Deepak et al. · 2019 · Structure
Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon
Van Nguyen, Thang, Lee, J. Eugene, Sweredoski, Michael J., Yang, Seung-Joo, Jeon, Seung-Je, Harrison, Joseph S., Yim, Jung-Hyuk, Lee, Sang Ghil, Handa, Hiroshi, Kuhlman, Brian et al. · 2016 · Molecular Cell
Harnessing the Power of Proteolysis for Targeted Protein Inactivation
Verma, Rati, Mohl, Dane, Deshaies, Raymond J. · 2020 · Molecular Cell
Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity
Wu, Hao, Yang, Ka, Zhang, Zhongrui, Leisten, Eric D., Li, Ziyuan, Xie, Haibo, Liu, Jin, Smith, Kerry A., Novakova, Zora, Barinka, Cyril et al. · 2019 · Journal of Medicinal Chemistry
E3 ligase ligand chemistries: from building blocks to protein degraders
Izidor Sosič, Aleša Bricelj, Christian Steinebach · 2022 · Chemical Society Reviews
Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer
William G. Kaelin · 2022 · Journal of Clinical Investigation
From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation
Oleinikovas, Vladas, Gainza, Pablo, Ryckmans, Thomas, Fasching, Bernhard, Thomä, Nicolas H. · 2024 · Annual Review of Pharmacology and Toxicology
Haven't got a glue: Protein surface variation for the design of molecular glue degraders
Kozicka, Zuzanna, Thomä, Nicolas Holger · 2021 · Cell Chemical Biology
Progress and Paradigms in Multiple Myeloma
Kenneth Carl Anderson · 2016 · Clinical Cancer Research
Bruton tyrosine kinase degradation as a therapeutic strategy for cancer
Dobrovolsky, Dennis, Wang, Eric S., Morrow, Sara, Leahy, Catharine, Faust, Tyler, Nowak, Radosław P., Donovan, Katherine A., Yang, Guang, Li, Zhengnian, Fischer, Eric S. et al. · 2019 · Blood
Translation termination factor GSPT1 is a phenotypically relevant off-target of heterobifunctional phthalimide degraders
Ishoey, Mette, Chorn, Someth, Singh, Natesh, Jaeger, Martin G., Brand, Matthias, Paulk, Joshiawa, Bauer, Sophie, Erb, Michael A., Parapatics, Katja, Müller, André C. et al. · 2018 · ACS Chemical Biology
Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy
Bonazzi, Simone, d’Hennezel, Eva, Beckwith, Rohan E.J., Xu, Lei, Fazal, Aleem, Magracheva, Anna, Ramesh, Radha, Cernijenko, Artiom, Antonakos, Brandon, Bhang, Hyo-eun C. et al. · 2023 · Cell Chemical Biology
Targeted degradation of the enhancer lysine acetyltransferases CBP and p300
Vannam, Raghu, Sayilgan, Jan, Ojeda, Samuel, Karakyriakou, Barbara, Hu, Eileen, Kreuzer, Johannes, Morris, Robert, Herrera Lopez, Xcanda Ixchel, Rai, Sumit, Haas, Wilhelm et al. · 2021 · Cell Chemical Biology
Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
Benjamin G. Barwick, Vikas Anand Gupta, Paula M. Vertino, Lawrence Boise · 2019 · Frontiers in Immunology
AirID, a novel proximity biotinylation enzyme, for analysis of protein–protein interactions
Kohki Kido, Satoshi Yamanaka, Shogo Nakano, Kou Motani, Souta Shinohara, Akira Nozawa, Hidetaka Kosako, Sohei Ito, Tatsuya Sawasaki · 2020 · eLife
Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders
Junichi Yamamoto, Takumi Ito, Yuki Yamaguchi, Hiroshi Handa · 2022 · Chemical Society Reviews
Prime time for PROTACs
Deshaies, Raymond J · 2015 · Nature Chemical Biology
Developing degraders: principles and perspectives on design and chemical space
Hannah J. Maple, Nat Clayden, Anne Baron, Callum Stacey, Robert L. Felix · 2019 · MedChemComm
Emerging degrader technologies engaging lysosomal pathways
Yu Ding, Dong Xing, Yiyan Fei, Boxun Lu · 2022 · Chemical Society Reviews
Visible-Light-Mediated Efficient Metal-Free Catalyst for α-Oxygenation of Tertiary Amines to Amides
Yu Zhang, Daniel Riemer, Waldemar Schilling, Jiri Kollmann, Shoubhik Das · 2018 · ACS Catalysis
Homo-PROTACs for the Chemical Knockdown of Cereblon
Christian Steinebach, Stefanie Lindner, Namrata D. Udeshi, D.R. Mani, Hannes Kehm, Simon Köpff, Steven A. Carr, Michael Gütschow, Jan Krönke · 2018 · ACS Chemical Biology
CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia
Hansen, Joshua D., Correa, Matthew, Alexander, Matt, Nagy, Mark, Huang, Dehua, Sapienza, John, Lu, Gang, LeBrun, Laurie A., Cathers, Brian E., Zhang, Weihong et al. · 2021 · Journal of Medicinal Chemistry
The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia
René Marke, Frank N. van Leeuwen, Blanca Scheijen · 2018 · Haematologica
Widespread intronic polyadenylation diversifies immune cell transcriptomes
Irtisha Singh, Shih‐Han Lee, Adam Samuel Sperling, Mehmet Samur, Yu‐Tzu Tai, Mariateresa Fulciniti, Nikhil C. Munshi, Christine Mayr, Christina S. Leslie · 2018 · Nature Communications
Targeted protein degradation: current and future challenges
Alexander Hanzl, Georg E. Winter · 2020 · Current Opinion in Chemical Biology
From Discovery to Bedside: Targeting the Ubiquitin System
Ingrid E. Wertz, Xiao‐Jing Wang · 2018 · Cell chemical biology
DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
Li, Fenglei, Hu, Qiaoyu, Zhang, Xianglei, Sun, Renhong, Liu, Zhuanghua, Wu, Sanan, Tian, Siyuan, Ma, Xinyue, Dai, Zhizhuo, Yang, Xiaobao et al. · 2022 · Nature Communications
The bone-marrow niche in MDS and MGUS: implications for AML and MM
Irene M. Ghobrial, Alexandre Detappe, Kenneth Carl Anderson, David P. Steensma · 2018 · Nature Reviews Clinical Oncology
Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells
Mattias Carlsten, Marcus Järås · 2019 · Frontiers in Immunology
Immunosurveillance and therapy of multiple myeloma are CD226 dependent
Camille Guillerey, Lucas Ferrari de Andrade, Slavica Vučković, Kim M. Miles, Shin Foong Ngiow, Michelle C.R. Yong, Michele W.L. Teng, Marco Colonna, David S. Ritchie, Martha Chesi et al. · 2015 · Journal of Clinical Investigation
Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments
Yoo Jin Jung, David Tweedie, Michael T. Scerba, Nigel H. Greig · 2019 · Frontiers in Cell and Developmental Biology
Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation
Aimo Kannt, Ivan Đikić · 2021 · Cell chemical biology
Quantifying Ubiquitin Signaling
Alban Ordureau, Christian Münch, J. Wade Harper · 2015 · Molecular Cell
Template-assisted covalent modification underlies activity of covalent molecular glues
Yen-Der Li, Michelle W. Ma, Muhammad Murtaza Hassan, Moritz Hunkeler, Mingxing Teng, Kedar Puvar, Justine C. Rutter, Ryan J. Lumpkin, Brittany Sandoval, Cyrus Y. Jin et al. · 2024 · Nature Chemical Biology
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
Benjamin G. Barwick, Paola E. Neri, Nizar Jacques Bahlis, Ajay K. Nooka, Madhav V. Dhodapkar, David L. Jaye, Craig C. Hofmeister, Jonathan L. Kaufman, Vikas Anand Gupta, Daniel Auclair et al. · 2019 · Nature Communications
An E3 ligase guide to the galaxy of small-molecule-induced protein degradation
Predrag Jevtić, Diane L. Haakonsen, Michael Rapé · 2021 · Cell chemical biology
Time-resolved in vivo ubiquitinome profiling by DIA-MS reveals USP7 targets on a proteome-wide scale
Martin Steger, Vadim Demichev, Mattias Backman, Uli Ohmayer, Phillip Ihmor, Stefan Müller, Markus Ralser, Henrik Daub · 2021 · Nature Communications
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics
Stephan M. Tirier, Jan‐Philipp Mallm, Simon Steiger, Alexandra Maria Poos, Mohamed H.S. Awwad, Nicola Giesen, Nicola Andrea Casiraghi, Hana Sušak, Katharina Bauer, Anja Baumann et al. · 2021 · Nature Communications
RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics
Elisabeth Salzer, Deniz N Cağdaş, Miroslav Hons, Emily Margaret Mace, Wojciech Garncarz, Özlem Yüce Petronczki, René Platzer, Laurène Pfajfer, Ivan Bilić, Sol A. Ban et al. · 2016 · Nature Immunology
Proteolysis-targeting chimeras with reduced off-targets
Tuan M. Nguyen, Vedagopuram Sreekanth, Arghya Deb, Praveen Kokkonda, Praveen K. Tiwari, Katherine A. Donovan, Veronika M. Shoba, Santosh Kumar Chaudhary, Jaron A. M. Mercer, Sophia Lai et al. · 2023 · Nature Chemistry
Hemoglobin switching’s surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin.
Bauer, Daniel E, Orkin, Stuart H · 2015 · Current Opinion in Genetics & Development
Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders
Steinebach, Christian, Ng, Yuen Lam Dora, Sosič, Izidor, Lee, Chih-Shia, Chen, Sirui, Lindner, Stefanie, Vu, Lan Phuong, Bricelj, Aleša, Haschemi, Reza, Monschke, Marius et al. · 2020 · Chemical Science
A proteome-wide atlas of drug mechanism of action
Dylan Charles Mitchell, Miljan Kuljanin, Jiaming Li, Jonathan G. Van Vranken, Nathan J. Bulloch, Devin K. Schweppe, Edward L. Huttlin, Steven P. Gygi · 2023 · Nature Biotechnology
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Ana Bela Sarmento‐Ribeiro, Andreas Scorilas, Ana Cristina Gonçalves, Thomas Efferth, Ioannis P. Trougakos · 2019 · Drug Resistance Updates
Altered RNA Processing in Cancer Pathogenesis and Therapy
Esther A. Obeng, Connor Stewart, Omar Ibrahim Abdel-Wahab · 2019 · Cancer Discovery
Chemical approaches to targeted protein degradation through modulation of the ubiquitin–proteasome pathway
Ian Collins, Hannah Wang, John Caldwell, Raj Chopra · 2017 · Biochemical Journal
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, Max, Sperling, Adam S., Ebert, Benjamin L. · 2021 · Nature Reviews Clinical Oncology
Multiple myeloma: the (r)evolution of current therapy and a glance into future
Annamaria Gullà, Kenneth Carl Anderson · 2020 · Haematologica
A p85α-osteopontin axis couples the receptor ICOS to sustained Bcl-6 expression by follicular helper and regulatory T cells
Jianmei Wu Leavenworth, Bert Verbinnen, Jie Yin, Huicong Huang, Harvey Cantor · 2014 · Nature Immunology
p63 is a cereblon substrate involved in thalidomide teratogenicity
Asatsuma-Okumura, Tomoko, Ando, Hideki, De Simone, Marco, Yamamoto, Junichi, Sato, Tomomi, Shimizu, Nobuyuki, Asakawa, Kazuhide, Yamaguchi, Yuki, Ito, Takumi, Guerrini, Luisa et al. · 2019 · Nature Chemical Biology
Driving E3 Ligase Substrate Specificity for Targeted Protein Degradation: Lessons from Nature and the Laboratory
Angus D. Cowan, Alessio Ciulli · 2022 · Annual Review of Biochemistry
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets
Kartik Sehgal, Rituparna Das, Lin Zhang, Rakesh Verma, Yanhong Deng, Mehmet Hakan Kocoglu, Juan C. Vasquez, Srinivas V. Koduru, Yan Ren, Maria Wang et al. · 2015 · Blood
Ligandability of E3 Ligases for Targeted Protein Degradation Applications
Belcher, Bridget P., Ward, Carl C., Nomura, Daniel K. · 2023 · Biochemistry
Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds
Kathryn Lagrue, Alexandre F. Carisey, David J. Morgan, Rajesh Chopra, Daniel M. Davis · 2015 · Blood
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Fink, Emma C., McConkey, Marie, Adams, Dylan N., Haldar, Saurav D., Kennedy, James A., Guirguis, Andrew A., Udeshi, Namrata D., Mani, D. R., Chen, Michelle, Liddicoat, Brian et al. · 2018 · Blood
Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back
Giada Bianchi, Kenneth Carl Anderson · 2014 · CA A Cancer Journal for Clinicians
Structural basis of thalidomide enantiomer binding to cereblon
Tomoyuki Mori, Takumi Ito, Shujie Liu, Hideki Ando, Satoshi Sakamoto, Yuki Yamaguchi, Etsuko Tokunaga, Norio Shibata, Hiroshi Handa, Toshio Hakoshima · 2018 · Scientific Reports
Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis
Matthew Ho, Emma L. Kavanagh, Luke Dunne, Paul Dowling, Li Zhang, Sinéad Lindsay, Despina Bazou, Chia Yin Goh, Cathal Hanley, Giada Bianchi et al. · 2019 · Cancers
Targeting MYC in multiple myeloma
Katarina Jovanović, Catherine Roche‐Lestienne, Irene M. Ghobrial, Thierry T.F. Facon, Bruno Quesnel, Salomon Manier · 2018 · Leukemia
The state of the art of PROTAC technologies for drug discovery
Chao Wang, Cangxin Zheng, Han Wang, Liangren Zhang, Zhenming Liu, Ping Xu · 2022 · European Journal of Medicinal Chemistry
Targeted protein degradation and the enzymology of degraders
Fisher, Stewart L, Phillips, Andrew J · 2018 · Current Opinion in Chemical Biology
Discovery of E3 Ligase Ligands for Target Protein Degradation
Jaeseok Lee, Young‐Jun Lee, Young Mee Jung, Ju Hyun Park, Hyuk Sang Yoo, Jongmin Park · 2022 · Molecules
Defining molecular glues with a dual-nanobody cannabidiol sensor
Cao, Shiyun, Kang, Shoukai, Mao, Haibin, Yao, Jiayu, Gu, Liangcai, Zheng, Ning · 2022 · Nature Communications
Tumor microenvironment (TME)-driven immune suppression in B cell malignancy
Nicole S. Nicholas, Benedetta Apollonio, Alan G. Ramsay · 2015 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Folate-Guided Protein Degradation by Immunomodulatory Imide Drug-Based Molecular Glues and Proteolysis Targeting Chimeras
He Chen, Jing Liu, H. Ümit Kanıskan, Wenyi Wei, Jian Jun Jin · 2021 · Journal of Medicinal Chemistry
How Thalidomide Works Against Cancer
A. Keith Stewart · 2014 · Science
Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity
Sievers, Quinlan L., Gasser, Jessica A., Cowley, Glenn S., Fischer, Eric S., Ebert, Benjamin L. · 2018 · Blood
Acute pharmacological degradation of Helios destabilizes regulatory T cells
Wang, Eric S., Verano, Alyssa L., Nowak, Radosław P., Yuan, J. Christine, Donovan, Katherine A., Eleuteri, Nicholas A., Yue, Hong, Ngo, Kenneth H., Lizotte, Patrick H., Gokhale, Prafulla C. et al. · 2021 · Nature Chemical Biology
Aryl Sulfonamides Degrade RBM39 and RBM23 by Recruitment to CRL4-DCAF15
Ting, Tabitha C., Goralski, Maria, Klein, Katherine, Wang, Baiyun, Kim, Jiwoong, Xie, Yang, Nijhawan, Deepak · 2019 · Cell Reports